Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

  1. Lookup NU author(s)
  2. Professor David Jones
Author(s)Jones DEJ, Boudes P, Swain M, Bowlus C, Galambos M, Bacon B, Doerffel Y, Gitlin N, Gordon S, Odin J, Sheridan D, Wörns M-A, Clark V, Corless L, Hartmann H, Jonas ME, Kremer A, Mells G, Buggisch P, Freilich B, Levy C, Vierling J, Bernstein D, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman M, Smith J, Choi Y-J, Steinberg A, Varga M, Chera H, Martin R, McWherter C, Hirschfield G
Publication type Article
JournalLancet Gastroenterology and Hepatology
Year2017
Volume2
Issue10
Pages716-726
ISSN (print)0140-6736
The full text of this item is currently under embargo and cannot be made publicly available until 14/02/2018.
PublisherElsevier
URLhttps://doi.org/10.1016/S2468-1253(17)30246-7
DOI10.1016/S2468-1253(17)30246-7
Actions    Link to this publication

Altmetrics provided by Altmetric

Share